We read with interest the manuscript of Pruneri et al. [1] concerning tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS). TILs were retrospectively studied in an extensive cohort of 1488 patients. DCIS studies are often underpowered due to limited patient numbers, and robust statistical analysis is frequently hampered by low recurrence rates. Therefore, Pruneri et al. [1] provide truly valuable information for the scientific and oncologic community. However, we do have some remarks regarding the conclusions of this study. [...
Although the prognostic and predictive significance of human epidermal growth factor receptor 2 (HER...
BACKGROUND: To assess the prognostic role of human epidermal growth factor receptor 2 (HER2) overexp...
Purpose: The immune microenvironment of breast ductal carcinoma in situ (DCIS) has yet to be fully e...
Background: Tumor-infiltrating lymphocytes (TILs) are a robust prognostic adjunct in invasive breast...
INTRODUCTION: The role of ductal carcinoma in situ (DCIS) component on the outcome of invasive breas...
© 2019, Cancer Research UK. Background: Previous studies have reported up to 50% of ductal carcinoma...
Background: HER2 is a well-established prognostic and predictive factor in invasive breast cancer. T...
This study aimed to characterize ductal carcinoma in situ (DCIS) according to human epidermal growth...
Increasing evidence suggests that the significance of the tumour immune microenvironment (TIME) for ...
BACKGROUND: The role of different subtypes of tumour infiltrating lymphocytes (TILs) in breast ducta...
Abstract Background Tumor infiltrating lymphocytes (TILs) have been shown to be associated with the ...
BACKGROUND: The immune microenvironment is an important modulator of tumour progression and treatmen...
Although the prognostic and predictive significance of human epidermal growth factor receptor 2 (HER...
Aims: Tumour‐infiltrating lymphocytes (TILs) are an important component of the immune response to ca...
Background: Breast ductal carcinoma in situ (DCIS) accounts for more than 20% of screen-detected br...
Although the prognostic and predictive significance of human epidermal growth factor receptor 2 (HER...
BACKGROUND: To assess the prognostic role of human epidermal growth factor receptor 2 (HER2) overexp...
Purpose: The immune microenvironment of breast ductal carcinoma in situ (DCIS) has yet to be fully e...
Background: Tumor-infiltrating lymphocytes (TILs) are a robust prognostic adjunct in invasive breast...
INTRODUCTION: The role of ductal carcinoma in situ (DCIS) component on the outcome of invasive breas...
© 2019, Cancer Research UK. Background: Previous studies have reported up to 50% of ductal carcinoma...
Background: HER2 is a well-established prognostic and predictive factor in invasive breast cancer. T...
This study aimed to characterize ductal carcinoma in situ (DCIS) according to human epidermal growth...
Increasing evidence suggests that the significance of the tumour immune microenvironment (TIME) for ...
BACKGROUND: The role of different subtypes of tumour infiltrating lymphocytes (TILs) in breast ducta...
Abstract Background Tumor infiltrating lymphocytes (TILs) have been shown to be associated with the ...
BACKGROUND: The immune microenvironment is an important modulator of tumour progression and treatmen...
Although the prognostic and predictive significance of human epidermal growth factor receptor 2 (HER...
Aims: Tumour‐infiltrating lymphocytes (TILs) are an important component of the immune response to ca...
Background: Breast ductal carcinoma in situ (DCIS) accounts for more than 20% of screen-detected br...
Although the prognostic and predictive significance of human epidermal growth factor receptor 2 (HER...
BACKGROUND: To assess the prognostic role of human epidermal growth factor receptor 2 (HER2) overexp...
Purpose: The immune microenvironment of breast ductal carcinoma in situ (DCIS) has yet to be fully e...